Published in Oncoimmunology on December 10, 2013
Update on neurological paraneoplastic syndromes. Curr Opin Oncol (2015) 0.90
CCR5 blockade for neuroinflammatory diseases - beyond control of HIV. Nat Rev Neurol (2016) 0.83
Guardian of Genetic Messenger-RNA-Binding Proteins. Biomolecules (2016) 0.80
The great masquerader of malignancy: chronic intestinal pseudo-obstruction. Biomark Res (2014) 0.76
CD4+ and CD8+ T cells are both needed to induce paraneoplastic neurological disease in a mouse model. Oncoimmunology (2016) 0.75
Small Cell Lung Cancer Accompanied by Tonsillar Metastasis and Anti-Hu Antibody-Associated Paraneoplastic Neuropathy: A Rare Case Report With Long-Term Survival. Medicine (Baltimore) (2015) 0.75
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. J Thorac Oncol (2016) 0.75
Movement and Other Neurodegenerative Syndromes in Patients with Systemic Rheumatic Diseases: A Case Series of 8 Patients and Review of the Literature. Medicine (Baltimore) (2015) 0.75
Multiple sequential antibody-associated syndromes with a recurrent mutated neuroblastoma. Neurology (2016) 0.75
Synchronous Adie's syndrome and type 1 antineuronal nuclear antibody (anti-Hu)-related paraneoplastic neurological syndromes as predictors of complete response in limited-stage small-cell lung cancer: A case report. Mol Clin Oncol (2017) 0.75
Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. J Biol Chem (1996) 5.82
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov (2010) 5.55
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain (2001) 5.04
Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) (1992) 3.21
Characterization and spatial distribution of the ELAV protein during Drosophila melanogaster development. J Neurobiol (1991) 3.12
The elav gene product of Drosophila, required in neurons, has three RNP consensus motifs. Science (1988) 3.03
Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol (2004) 2.91
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity (2013) 2.86
A hierarchy of Hu RNA binding proteins in developing and adult neurons. J Neurosci (1997) 2.76
Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis. Ann Neurol (1990) 2.58
Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol (2002) 2.48
Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol (1997) 2.19
Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain (2012) 2.17
Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med (1998) 2.11
Purification and properties of HuD, a neuronal RNA-binding protein. J Biol Chem (1996) 2.00
Cerebrospinal fluid study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry (2009) 1.96
Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol (1999) 1.91
Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology (1985) 1.86
Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med (1986) 1.79
Role of HuD and other RNA-binding proteins in neural development and plasticity. J Neurosci Res (2002) 1.76
Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. J Clin Oncol (2004) 1.71
Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology (1990) 1.65
RNA-protein interactions and control of mRNA stability in neurons. J Neurosci Res (2008) 1.55
Anti-Hu-associated paraneoplastic sensory neuropathy responding to early aggressive immunotherapy: report of two cases and review of literature. Muscle Nerve (1997) 1.55
Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet (1993) 1.54
Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology (1992) 1.47
Immune response in lung cancer mouse model mimics human anti-Hu reactivity. J Neuroimmunol (2009) 1.47
Combination checkpoint blockade--taking melanoma immunotherapy to the next level. N Engl J Med (2013) 1.45
Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol (2002) 1.43
Cross-reactive T-cell receptors in tumor and paraneoplastic target tissue. Arch Neurol (2009) 1.40
Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry (1996) 1.39
Lack of association between human leukocyte antigens and the anti-Hu syndrome in patients with small-cell lung cancer. Neurology (1998) 1.39
Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol (1995) 1.37
Cytoplasmic localization is required for the mammalian ELAV-like protein HuD to induce neuronal differentiation. Genes Cells (1999) 1.37
Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer (1995) 1.36
Celiac disease: an immunological jigsaw. Immunity (2012) 1.33
Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity. Neurology (1994) 1.32
Neuronal Elav-like (Hu) proteins regulate RNA splicing and abundance to control glutamate levels and neuronal excitability. Neuron (2012) 1.27
Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Neurology (1991) 1.26
Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer (2004) 1.20
Anti-HuD-induced neuronal apoptosis underlying paraneoplastic gut dysmotility. Gastroenterology (2003) 1.19
T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology (1998) 1.18
Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol (2011) 1.17
New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget (2011) 1.15
Celiac disease and transglutaminase 2: a model for posttranslational modification of antigens and HLA association in the pathogenesis of autoimmune disorders. Curr Opin Immunol (2011) 1.13
Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology (1995) 1.11
Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on α4 integrin. Brain (2011) 1.10
T cell response to Hu-D peptides in patients with anti-Hu syndrome. J Neurooncol (2005) 1.09
Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest (2009) 1.08
Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology (2013) 1.07
Onconeural antibodies in sera from patients with various types of tumours. Cancer Immunol Immunother (2009) 1.06
Type IIa ('anti-Hu') antineuronal antibodies produce destruction of rat cerebellar granule neurons in vitro. Neurology (1993) 1.06
Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology (1999) 1.02
Paraneoplastic demyelinating neuropathy, subacute sensory neuropathy, and anti-Hu antibodies: clinicopathological study of an autopsy case. Muscle Nerve (1998) 1.00
Regulatory T cells in paraneoplastic neurological syndromes. J Neuroimmunol (2008) 0.98
Unbiased identification of target antigens of CD8+ T cells with combinatorial libraries coding for short peptides. Nat Med (2012) 0.97
Paraneoplasia and autoimmunologic injury of the nervous system: the anti-Hu syndrome. Brain Pathol (1993) 0.97
Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HHD mouse and human. J Neuroimmunol (2003) 0.97
DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res (1998) 0.96
A T-cell receptor associated with naturally occurring human tumor immunity. Proc Natl Acad Sci U S A (2007) 0.96
Anti-Hu antibody titre and brain metastases before and after treatment for small cell lung cancer. J Neurol Neurosurg Psychiatry (1999) 0.95
Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain (2004) 0.94
Do MHCII-presented neoantigens drive type 1 diabetes and other autoimmune diseases? Cold Spring Harb Perspect Med (2012) 0.92
Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis. Neurology (1994) 0.92
Intrathecal synthesis of the anti-Hu antibody in patients with paraneoplastic encephalomyelitis or sensory neuronopathy: clinical-immunologic correlation. Neurology (1994) 0.91
Observing the invisible: successful tumor immunity in humans. Nat Immunol (2003) 0.90
Neurons as targets for T cells in the nervous system. Trends Neurosci (2013) 0.90
Ganglionitis in paraneoplastic subacute sensory neuronopathy: a morphologic study. Neurology (1997) 0.89
Pattern of epitopic reactivity of the anti-Hu antibody on HuD with and without paraneoplastic syndrome. J Neurol Neurosurg Psychiatry (1999) 0.88
Molecular analysis of the HuD gene encoding a paraneoplastic encephalomyelitis antigen in human lung cancer cell lines. Cancer Res (1994) 0.88
Antibody types and IgG subclasses in paraneoplastic neurological syndromes. J Neurol Sci (2001) 0.88
Increased expression and localization of the RNA-binding protein HuD and GAP-43 mRNA to cytoplasmic granules in DRG neurons during nerve regeneration. Exp Neurol (2003) 0.88
Cell surface expression of paraneoplastic encephalomyelitis/sensory neuronopathy-associated Hu antigens in small-cell lung cancers and neuroblastomas. Neurology (1997) 0.87
Neuroprotective intervention by interferon-γ blockade prevents CD8+ T cell-mediated dendrite and synapse loss. J Exp Med (2013) 0.85
Tolerance to the neuron-specific paraneoplastic HuD antigen. PLoS One (2009) 0.85
Nuclear localization of anti-Hu antibody is not associated with in vitro cytotoxicity. J Neuroimmunol (1994) 0.85
IgG-mediated cytotoxicity to myenteric plexus cultures in patients with paraneoplastic neurological syndromes. J Autoimmun (2000) 0.84
HuD promotes BDNF expression in brain neurons via selective stabilization of the BDNF long 3'UTR mRNA. PLoS One (2013) 0.84
No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies. Cancer Immunol Immunother (2007) 0.84
Oligoclonal T-cells in blood and target tissues of patients with anti-Hu syndrome. J Neuroimmunol (2002) 0.84
Molecular analysis of the HuD gene in neuroendocrine lung cancers. Lung Cancer (2010) 0.84
HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes. J Neuroimmunol (2010) 0.82
Cutting edge: neuronal recognition by CD8 T cells elicits central diabetes insipidus. J Immunol (2012) 0.82
Absence of HuD gene mutations in paraneoplastic small cell lung cancer tissue. Neurology (1998) 0.82
Induction of anti-Purkinje cell antibodies in vivo by immunizing with a recombinant 52-kDa paraneoplastic cerebellar degeneration-associated protein. J Neuroimmunol (1995) 0.81
Effects of antineuronal antibodies from patients with paraneoplastic neurological syndrome on primary-cultured neurons. J Neurol Sci (2004) 0.81
Expression of lymphocyte, macrophage and class I and II major histocompatibility complex antigens in normal human dorsal root ganglia. J Neurol Sci (1990) 0.80
Demonstration of anti-HuD specific oligoclonal bands in the cerebrospinal fluid from patients with paraneoplastic neurological syndromes. Qualitative evidence of anti-HuD specific IgG-synthesis in the central nervous system. J Neuroimmunol (2000) 0.79
Three sensitive assays do not provide evidence for circulating HuD-specific T cells in the blood of patients with paraneoplastic neurological syndromes with anti-Hu antibodies. Neuro Oncol (2012) 0.78
Imbalances in circulating lymphocyte subsets in Hu antibody associated paraneoplastic neurological syndromes. Eur J Neurol (2007) 0.78
Functional and direct interaction between the RNA binding protein HuD and active Akt1. Nucleic Acids Res (2011) 0.78
Disturbance in the serum IgG subclass distribution in patients with anti-Hu positive paraneoplastic neurological syndromes. Eur J Neurol (2002) 0.77
Expression of peptide and other markers in lung cancer cell lines. Recent Results Cancer Res (1985) 0.76
Pathogenesis and treatment of paraneoplastic neurologic syndrome. Expert Rev Neurother (2002) 0.76
Elevated numbers of regulatory T cells, central memory T cells and class-switched B cells in cerebrospinal fluid of patients with anti-Hu antibody associated paraneoplastic neurological syndromes. J Neuroimmunol (2013) 0.76
Expression of HuD (a paraneoplastic encephalomyelitis antigen) mRNA in lung cancer. J Korean Med Sci (1997) 0.76